Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

September 30, 2015

Conditions
Solid TumorsHematologic MalignanciesHepatic Impairment
Interventions
DRUG

Carfilzomib

Carfilzomib was administered by IV injection over 30 minutes

Trial Locations (11)

Unknown

Karmanos Cancer Institute, Detroit

Duke Cancer Institute, Durham

Gabrail Cancer Center, Canton

Tennessee Oncology, PLLC, Nashville

Evergreen Hematology and Oncology, Spokane

Institut Gustave Roussy, Paris

University Medical Centre Utrecht, Utrecht

Northern Ireland Cancer Trials Centre - Queen's University Belfast TriaIs Centre, Belfast

Beatson West of Scotland Cancer Centre, Glasgow

Velindre Hospital, Cardlff

Sir Bobby Robson Cancer Trials Research Centre, Newcastle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT01949545 - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment | Biotech Hunter | Biotech Hunter